関連する実験動画
Updated: Sep 16, 2026

11:10
Hyperinsulinemic-euglycemic Clamps in Conscious, Unrestrained Mice
Published on: November 16, 2011
まとめ
反応性低血糖症の成人では,臓のA細胞機能が不十分である可能性があり,これは,断食中のグルカゴン濃度の低下によって示される. このA細胞欠乏症は,成人における反応性低血糖症に寄与する要因である可能性があります.
科学分野:
- エンドクリノロジー エンドクリノロジー
- メタボリック障害 メタボリック障害
- ホルモン規制 ホルモン規制
背景:
- 反応性低血糖症は,食事後の低血糖値が特徴である状態です.
- 反応性低血糖症における臓アルファ細胞 (A細胞) 機能の役割は完全に理解されていません.
研究 の 目的:
- 反応性低血糖症の患者における臓A細胞の機能を調査する.
- 反応性低血糖症の患者と正常な被験者の間のホルモン分泌パターンを比較する.
主な方法:
- 測定された血清グルコース,インスリン,グルカゴン (A細胞および合計),成長ホルモン,コルチゾール,トリヨドチロニン,チロキシン.
- 断食時のホルモンレベルと,口服によるグルコース,アルギニン,肉食に対する反応を評価した.
- 31人の症状のある患者 (7人が反応性低血糖症) と11人の正常な被験者を含む.
主要な成果:
- 反応性低血糖症の患者 (2群) は,正常な被験者 (1群) と比較して, signicantly lower fasting serum A-cell glucagon (IRGA) 濃度を示した.
- 口服したグルコース,アルギニン,および肉は,両方のグループで同様に全グルカゴン (IRGT) レベルを刺激しました.
- インスリン,成長ホルモン,コルチゾール,トリヨドチロニン,チロキシンの分泌は,グループによって有意に異なっていなかった.
結論:
- 臓のA細胞不全は,成人における反応性低血糖症の発生に寄与する可能性があります.
- 反応性低血糖症患者の断食中のグルカゴン濃度の低下は,A細胞貯蔵量の低下を示唆する.
関連する概念動画
Hormones Regulating Blood Glucose
Insulin is released by beta cells of the pancreas when blood glucose levels are high. It facilitates glucose absorption and utilization in insulin-dependent cells with insulin receptors on their plasma membranes. Insulin promotes glucose uptake by increasing the number of glucose transport proteins in the cell membrane, allowing glucose to enter the cell. As a result, glucose utilization and ATP production are enhanced.
In addition to accelerating glucose uptake and utilization, insulin has...
In addition to accelerating glucose uptake and utilization, insulin has...
Glucose Homeostasis: Pancreatic Islets and Insulin Secretion
The pancreatic islets comprising only 1%-2% of the volume are highly vascularized and innervated mini-organs. They contain five endocrine cell types, including β cells that secrete insulin, which is synthesized as a single polypeptide chain, preproinsulin, processed to proinsulin, and finally to insulin and C-peptide. This process is complex and regulated, involving the Golgi complex, the endoplasmic reticulum, and the secretory granules of the β cell.
Insulin and C-peptide are co-secreted in...
Insulin and C-peptide are co-secreted in...
Diabetes: Symptoms, Diagnosis, and Complications
For most patients, experiencing several weeks of polyuria, polydipsia, fatigue, and significant weight loss may indicate the presence of diabetes. Furthermore, adults displaying the phenotypic appearance of type 2 diabetes (particularly those who are obese and not initially insulin-requiring), may have islet cell autoantibodies, suggesting autoimmune-mediated β cell destruction and a diagnosis of latent autoimmune diabetes of adults (LADA). The categorization of glucose homeostasis is based on...
Hypoglycemia and Glucagon
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
Type I Diabetes II: Pathophysiology
Type 1 diabetes mellitus arises from an immune-mediated destruction of pancreatic β-cells, resulting in an absolute deficiency of insulin. This process develops in genetically susceptible individuals when autoimmunity, environmental exposures, and immunologic dysregulation converge to trigger a targeted attack on the insulin-producing cells of the pancreas. The β-cells are located within the islets of Langerhans and are essential for regulating blood glucose by facilitating cellular uptake of...
Hypoglycemia
Hypoglycemia is a blood glucose level below 70 mg/dL. It commonly occurs in individuals using insulin or insulin-secreting drugs, but may also arise in non-diabetic conditions. People with type 1 diabetes are at the highest risk because they depend on exogenous insulin. People with type 2 diabetes are also at risk, especially when treated with insulin or medications such as sulfonylureas, which increase insulin release regardless of blood glucose levels. It develops when insulin levels exceed...

